General Cancer News
Top Stories
Studies From Mayo Clinic In The Area Of Cervical Cancer Screening Risk Factors Published
POSTED: May 14, 2008Data detailed in 'Higher incidence of abnormal Pap smears in women with inflammatory bowel disease' have been presented. "Immunosuppression results in a higher incidence of cervical dysplasia compared with healthy controls. We examined the relationship between immunomodulator use and the presence of abnormal cervical histology in women with inflammatory...
FDA Approves HIFU Clinical Trial For Recurrent Prostate Cancer
POSTED: May 14, 2008DELAND, Fla., -- USHIFU, LLC, the clinical trial management provider for Focus Surgery, Inc. (Indianapolis, IN), is pleased to announce conditional written approval pending minor changes to the protocol from the FDA to begin a pivotal trial for the treatment of recurrent prostate cancer with the Sonablate(R) 500 in men who have failed external b...
Oncolin Therapeutics Announces Its New 'Super Cell Blocker', ONC-127, Has Shown Effectiveness In Treating Cancer
POSTED: May 14, 2008HOUSTON -- Oncolin Therapeutics, Inc., announces that its new Super Cell Blocker, ONC-127, has been effective in treating animals that have been implanted with human tumors in their brains. This technology has extended the life of animals in a preclinical environment. The Super Cell Blocker, ONC-127, drug candidate is a major breakthrough in ...
Compugen Announces Discovery Of Blood Based Biomarker For Diagnosis Of Lung Cancer
POSTED: May 14, 2008Compugen Ltd. announced the discovery and experimental verification of CGEN-438, a potential blood based biomarker for lung cancer. CGEN-438 is novel splice variant peptide of delta-like protein 3 precursor (DLL3). Importantly, the Compugen discovered biomarker is a peptide that is secreted from the cell into the bloodstream, whereas the previously know...
Arsenic Used To Fight Warrior Cancer Cells
POSTED: May 14, 2008BOSTON -- Medical researchers in Boston say arsenic can be used in conjunction with chemotherapy to treat chronic myeloid leukemia. The research team led by Dr. Pier Paolo Pandolfi , a Harvard Medical School professor and head of the Cancer Genetics Program in Beth Israel Deaconess Medical Center, found that arsenic-based therapies successful...
Study Says New Radiation Therapy Technology For Breast Cancer Helps Protect Tissue, Adds Options For Patients
POSTED: May 14, 2008SAN DIEGO -- New research conducted at Moores Cancer Center at University of California, San Diego shows that the SAVI(TM) breast brachytherapy applicator, a new approach for delivering accelerated partial breast irradiation (APBI), may provide better protection of healthy tissue than other partial breast irradiation methods. The research tea...
TYKERB To Be Investigated In Landmark Early Breast Cancer Trial
POSTED: May 14, 2008PHILADELPHIA -- GlaxoSmithKline (GSK), in collaboration with the Breast International Group (BIG), a leading academic breast cancer research network, and one of its member groups, the Spanish Breast Cancer Cooperative Group (SOLTI), today announced the start of a global Phase III study that will examine the role of TYKERB(R) in the treatment o...
Findings From University Of Chicago Broaden Understanding Of Colon Cancer Therapy
POSTED: May 14, 2008Current study results from the report, 'Epidermal growth factor receptor controls flat dysplastic aberrant crypt foci development and colon cancer progression in the rat azoxymethane model,' have been published. "Colonic carcinogenesis deranges growth-regulating epidermal growth factor receptors (EGFR). We previously showed that EGFR signals were up-reg...
Colon Cancer: The Disease Is No Laughing Matter
POSTED: May 14, 2008There are few things the average person doesn't generally bring up in conversation: politics, religion and colonoscopies. The thought of someone probing your nether regions might make the average man or woman slightly uncomfortable. It's the fear of the unknown, medical experts say, that inhibits potential patients from taking the initiative to ge...
Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
POSTED: May 14, 2008SAN DIEGO -- Nventa Biopharmaceuticals Corporation today announced positive immunological data from the third cohort of its ongoing Phase 1 clinical trial of its lead product candidate, HspE7, in patients with cervical intraepithelial neoplasia, or CIN, a precursor to cervical cancer. HPV 16 E7-specific T-cell responses were elicited in all four...
